Healthy volunteers help test new chikungunya drug safety

NCT ID NCT04441905

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 35 times

Summary

This early-stage study tested a single dose of an experimental drug called SAR440894 in 42 healthy adults aged 18 to 45. The main goal was to check if the drug is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo, and researchers monitored them for about 5 months for side effects. This study does not aim to treat or prevent chikungunya, but to gather important safety information for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit

    Durham, North Carolina, 27710, United States

  • PPD - Austin Clinical Research Unit

    Austin, Texas, 78744-1645, United States

  • Pharmaceutical Product Development - Orlando Clinical Research Unit

    Orlando, Florida, 32806, United States

Conditions

Explore the condition pages connected to this study.